

Application Serial No. 09/478,977

Customer No.: 26021

Reply to Office Action of November 8, 2004

PATENT  
89188.0007

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-64. (Canceled)

65. (Currently amended) An antagonist that specifically binds to a denatured collagen or collagens but binds to the native triple helical form of each of said collagens with substantially reduced affinity and wherein said antagonist inhibits angiogenesis, wherein the antagonist is an antibody ~~The antagonist of claim 10 or claim 69 wherein said monoclonal antibody is a monoclonal antibody~~ having the binding specificity of monoclonal antibody HUI77.

66. (Currently amended) An antagonist that specifically binds to a denatured collagen or collagens but binds to the native triple helical form of each of said collagens with substantially reduced affinity and wherein said antagonist inhibits angiogenesis, wherein the antagonist is an antibody ~~The antagonist of claim 10 or claim 69 wherein said monoclonal antibody is a monoclonal antibody~~ having the binding specificity of monoclonal antibody HUTV26.

67. (Currently amended) An antagonist that specifically binds to a denatured collagen or collagens but binds to the native triple helical form of each of said collagens with substantially reduced affinity and wherein said antagonist inhibits angiogenesis, wherein the antagonist is an antibody ~~The antagonist of claim 10 or claim 69 wherein said monoclonal antibody is a monoclonal antibody~~ having the binding specificity of monoclonal antibody XL313.

68-83. (Canceled)